Cargando…

Integration of metabolomics, lipidomics and clinical data using a machine learning method

BACKGROUND: The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivot...

Descripción completa

Detalles Bibliográficos
Autores principales: Acharjee, Animesh, Ament, Zsuzsanna, West, James A., Stanley, Elizabeth, Griffin, Julian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133491/
https://www.ncbi.nlm.nih.gov/pubmed/28185575
http://dx.doi.org/10.1186/s12859-016-1292-2
_version_ 1782471273210707968
author Acharjee, Animesh
Ament, Zsuzsanna
West, James A.
Stanley, Elizabeth
Griffin, Julian L.
author_facet Acharjee, Animesh
Ament, Zsuzsanna
West, James A.
Stanley, Elizabeth
Griffin, Julian L.
author_sort Acharjee, Animesh
collection PubMed
description BACKGROUND: The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivotal role in lipid and carbohydrate metabolism and have been highlighted as potential treatments for obesity. This realisation started a search for NR agonists in order to understand and successfully treat MetS and associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesity and cardiovascular disease. The most studied NRs for treating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-α, PPAR-γ, and PPAR-δ. However, prolonged PPAR treatment in animal models has led to adverse side effects including increased risk of a number of cancers, but how these receptors change metabolism long term in terms of pathology, despite many beneficial effects shorter term, is not fully understood. In the current study, changes in male Sprague Dawley rat liver caused by dietary treatment with a PPAR-pan (PPAR-α, −γ, and –δ) agonist were profiled by classical toxicology (clinical chemistry) and high throughput metabolomics and lipidomics approaches using mass spectrometry. RESULTS: In order to integrate an extensive set of nine different multivariate metabolic and lipidomics datasets with classical toxicological parameters we developed a hypotheses free, data driven machine learning approach. From the data analysis, we examined how the nine datasets were able to model dose and clinical chemistry results, with the different datasets having very different information content. CONCLUSIONS: We found lipidomics (Direct Infusion-Mass Spectrometry) data the most predictive for different dose responses. In addition, associations with the metabolic and lipidomic data with aspartate amino transaminase (AST), a hepatic leakage enzyme to assess organ damage, and albumin, indicative of altered liver synthetic function, were established. Furthermore, by establishing correlations and network connections between eicosanoids, phospholipids and triacylglycerols, we provide evidence that these lipids function as a key link between inflammatory processes and intermediary metabolism. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12859-016-1292-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5133491
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51334912016-12-15 Integration of metabolomics, lipidomics and clinical data using a machine learning method Acharjee, Animesh Ament, Zsuzsanna West, James A. Stanley, Elizabeth Griffin, Julian L. BMC Bioinformatics Research BACKGROUND: The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivotal role in lipid and carbohydrate metabolism and have been highlighted as potential treatments for obesity. This realisation started a search for NR agonists in order to understand and successfully treat MetS and associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesity and cardiovascular disease. The most studied NRs for treating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-α, PPAR-γ, and PPAR-δ. However, prolonged PPAR treatment in animal models has led to adverse side effects including increased risk of a number of cancers, but how these receptors change metabolism long term in terms of pathology, despite many beneficial effects shorter term, is not fully understood. In the current study, changes in male Sprague Dawley rat liver caused by dietary treatment with a PPAR-pan (PPAR-α, −γ, and –δ) agonist were profiled by classical toxicology (clinical chemistry) and high throughput metabolomics and lipidomics approaches using mass spectrometry. RESULTS: In order to integrate an extensive set of nine different multivariate metabolic and lipidomics datasets with classical toxicological parameters we developed a hypotheses free, data driven machine learning approach. From the data analysis, we examined how the nine datasets were able to model dose and clinical chemistry results, with the different datasets having very different information content. CONCLUSIONS: We found lipidomics (Direct Infusion-Mass Spectrometry) data the most predictive for different dose responses. In addition, associations with the metabolic and lipidomic data with aspartate amino transaminase (AST), a hepatic leakage enzyme to assess organ damage, and albumin, indicative of altered liver synthetic function, were established. Furthermore, by establishing correlations and network connections between eicosanoids, phospholipids and triacylglycerols, we provide evidence that these lipids function as a key link between inflammatory processes and intermediary metabolism. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12859-016-1292-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-22 /pmc/articles/PMC5133491/ /pubmed/28185575 http://dx.doi.org/10.1186/s12859-016-1292-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Acharjee, Animesh
Ament, Zsuzsanna
West, James A.
Stanley, Elizabeth
Griffin, Julian L.
Integration of metabolomics, lipidomics and clinical data using a machine learning method
title Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_full Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_fullStr Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_full_unstemmed Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_short Integration of metabolomics, lipidomics and clinical data using a machine learning method
title_sort integration of metabolomics, lipidomics and clinical data using a machine learning method
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133491/
https://www.ncbi.nlm.nih.gov/pubmed/28185575
http://dx.doi.org/10.1186/s12859-016-1292-2
work_keys_str_mv AT acharjeeanimesh integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT amentzsuzsanna integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT westjamesa integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT stanleyelizabeth integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod
AT griffinjulianl integrationofmetabolomicslipidomicsandclinicaldatausingamachinelearningmethod